James Paton Bloomberg

A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.

Two years into the pandemic, a mutated version of the omicron variant, known as BA.2, has become the latest challenge to taming COVID-19.

The pursuit of second-generation Covid vaccines, including shots that could offer broader protection against a range of emerging coronavirus variants, is intensifying in the face of the omicron threat.

As Merck & Co. races ahead with an experimental pill that could play a pivotal role in the fight against Covid-19, efforts are intensifying to bring the drug to developing countries that have struggled to vaccinate their populations.

On Jan. 23, 2020, the day the novel coronavirus forced the Chinese city of Wuhan into lockdown, two American doctors named Seth Berkley and Richard Hatchett met at the bar of the Hard Rock Hotel in Davos, Switzerland, to talk about vaccines.

Growing worries that AstraZeneca Plc's Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul.

Just weeks into the rollout of vaccines to combat Covid-19, researchers are shifting their focus to a new class of potential shots to take on the threat posed by fast-spreading mutations.

On the day Britain began immunizing its population with a Covid-19 shot developed by Germany's BioNTech SE and the U.S.'s Pfizer Inc., a peer-reviewed study of the U.K.'s homegrown vaccine left some key questions unanswered.

Now that Britain has become the first western country to approve a Covid-19 shot, the spotlight shifts to the high-stakes rollout. Vaccinating the country's roughly 67 million people won't happen overnight. The UK has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people.

The U.K. became the first western country to approve a Covid-19 vaccine, with its regulator clearing Pfizer Inc. and BioNTech SE's shot ahead of decisions in the U.S. and European Union.

AstraZeneca Plc's Covid-19 vaccine looks like it's headed for an additional global trial as the drugmaker tries to clear up uncertainty and confusion surrounding favorable results in its current study.

AstraZeneca Plc and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error.

Trial successes from Pfizer Inc. and Moderna Inc. have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the U.S., is counting on another company's shot to escape the crisis.

The University of Oxford confirmed that the Covid-19 vaccine it's developing with AstraZeneca Plc produced strong immune responses in older adults in an early study, with pivotal findings from the final phase of trials expected in the coming weeks.

In early January, about the only thing the world's scientists knew for sure about the novel coronavirus was its genetic profile. Now, some 300 days later, vaccine developers are on the brink of a major victory against a pathogen that's inflicted untold personal and economic damage.

A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.

Two years into the pandemic, a mutated version of the omicron variant, known as BA.2, has become the latest challenge to taming COVID-19.

The pursuit of second-generation Covid vaccines, including shots that could offer broader protection against a range of emerging coronavirus variants, is intensifying in the face of the omicron threat.

As Merck & Co. races ahead with an experimental pill that could play a pivotal role in the fight against Covid-19, efforts are intensifying to bring the drug to developing countries that have struggled to vaccinate their populations.

On Jan. 23, 2020, the day the novel coronavirus forced the Chinese city of Wuhan into lockdown, two American doctors named Seth Berkley and Richard Hatchett met at the bar of the Hard Rock Hotel in Davos, Switzerland, to talk about vaccines.

Growing worries that AstraZeneca Plc's Covid-19 vaccine causes rare blood clots could hinder immunization campaigns across the world, from London to Seoul.

Just weeks into the rollout of vaccines to combat Covid-19, researchers are shifting their focus to a new class of potential shots to take on the threat posed by fast-spreading mutations.

On the day Britain began immunizing its population with a Covid-19 shot developed by Germany's BioNTech SE and the U.S.'s Pfizer Inc., a peer-reviewed study of the U.K.'s homegrown vaccine left some key questions unanswered.

Now that Britain has become the first western country to approve a Covid-19 shot, the spotlight shifts to the high-stakes rollout. Vaccinating the country's roughly 67 million people won't happen overnight. The UK has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people.

The U.K. became the first western country to approve a Covid-19 vaccine, with its regulator clearing Pfizer Inc. and BioNTech SE's shot ahead of decisions in the U.S. and European Union.

AstraZeneca Plc's Covid-19 vaccine looks like it's headed for an additional global trial as the drugmaker tries to clear up uncertainty and confusion surrounding favorable results in its current study.

AstraZeneca Plc and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error.

Trial successes from Pfizer Inc. and Moderna Inc. have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, outside of rich nations like the U.S., is counting on another company's shot to escape the crisis.

The University of Oxford confirmed that the Covid-19 vaccine it's developing with AstraZeneca Plc produced strong immune responses in older adults in an early study, with pivotal findings from the final phase of trials expected in the coming weeks.

In early January, about the only thing the world's scientists knew for sure about the novel coronavirus was its genetic profile. Now, some 300 days later, vaccine developers are on the brink of a major victory against a pathogen that's inflicted untold personal and economic damage.